Celsius Holdings Inc (CELH): Street Finally Waking Up

The Vanguard Group, Inc. recently announced the acquisition of new stake in Celsius Holdings Inc (NASDAQ:CELH). The institutional investor has increased its shareholding in the Consumer Defensive company by 18.78% to 14.31 million shares with purchase of 2.26 million shares. This fresh investment now brings its stake to 6.18% valued currently at $780.43 million. In addition, BlackRock Fund Advisors raised its holdings by 1.15 million to 12.08 million shares. And SSgA Funds Management, Inc. has lifted its position by 9.63% or 0.36 million shares – to 4.12 million shares.

Currently, there are 229.15M common shares owned by the public and among those 144.71M shares have been available to trade.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Insiders at the company have transacted a total of 48 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 16 of these insider trades were purchases, accounting for 9,725,410 shares. Insider sales of the common stock occurred on 32 occasions, with total insider shares sold totaling 3,899,373 shares.

The top 3 mutual fund holders in Celsius Holdings Inc are Fidelity Blue Chip Growth Fund, JPMorgan Large Cap Growth Fund, and iShares Core S&P Mid Cap ETF. Fidelity Blue Chip Growth Fund owns 7.29 million shares of the company’s stock, all valued at over $397.63 million. The company sold -1.33 million shares recently to bring their total holdings to about 3.15% of the shares outstanding. iShares Core S&P Mid Cap ETF bought 4075.0 shares to bring its total holdings to over 4.5 million shares at a value of $245.61 million. iShares Core S&P Mid Cap ETF now owns shares totaling to 1.95% of the shares outstanding.

However, the script later moved the day high at 54.67, up 1.28%. The company’s stock has a 5-day price change of -12.75% and -8.12% over the past three months. CELH shares are trading -3.42% year to date (YTD), with the 12-month market performance up to 61.50% higher. It has a 12-month low price of $26.75 and touched a high of $68.95 over the same period. CELH has an average intraday trading volume of 5.26 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -6.23%, -2.35%, and 4.32% respectively.

Institutional ownership of Celsius Holdings Inc (NASDAQ: CELH) shares accounts for 61.12% of the company’s 229.15M shares outstanding. Mutual fund holders own 23.31%, while other institutional holders and individual stakeholders account for 38.19% and 23.10% respectively.

It has a market capitalization of $12.20B and a beta (3y monthly) value of 1.72. The stock’s trailing 12-month PE ratio is 106.94, while the earnings-per-share (ttm) stands at $0.49. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.53% over the week and 5.57% over the month.

Analysts forecast that Celsius Holdings Inc (CELH) will achieve an EPS of $Celularity Inc. for the current quarter, $0.31 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $Clean Harbors, Inc. while analysts give the company a high EPS estimate of $Creative Medical Technology Hol. Comparatively, EPS for the current quarter was $Celcuity Inc. a year ago. Earnings per share for the fiscal year are expected to increase by 186.53%, and 26.13% over the next financial year.

Looking at the support for the CELH, a number of firms have released research notes about the stock. BofA Securities stated their Neutral rating for the stock in a research note on January 19, 2024, with the firm’s price target at $65.

Most Popular

Related Posts